Article
Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial).
Cancer chemotherapy and pharmacology - 15 Feb 2025
Hanrath Maarten A, Banken Evi, van den Wildenberg Sebastian A H, van de Kerkhof Daan, Moes Dirk Jan A R, Boisdron-Celle Michele, van den Bosch Bianca J C, Bax Ramon, Bet Pierre M, Maring Jan Gerard, Creemers Geert-Jan M, van Hellemond Irene E G, Deenen Maarten J
Abstract excerpt
PURPOSE: In 20-30% of the patients, fluoropyrimidines (5-FU) based chemotherapy leads to severe toxicity, which is associated with dihydropyridine dehydrogenase (DPD) deficiency. Therefore, DPYD genotyping became standard practice before treatment with fluoropyrimidines. Nevertheless, only 17% of the patients with severe toxicity have a DPYD variant. Therefore, an urgent need persists to investigate other...
Read the complete abstract on PubMedTopics
- Humans
- Fluorouracil
- Male
- Thymine
- Female
- Middle Aged
- Prospective Studies
- Aged
- Dihydrouracil Dehydrogenase (NADP)
- Gastrointestinal Neoplasms
- Antimetabolites, Antineoplastic
- Uracil
- Adult
- Biomarkers, Tumor
- Biomarkers
- Aged, 80 and over
- Genotype